Method for preparing sperm for carrying out intrauterine insemination |
|||||||||||||||||||||||||
|
IPC classes for russian patent Method for preparing sperm for carrying out intrauterine insemination (RU 2317072):
Method for treating cases of secretory masculine infertility form / 2317071
Method involves introducing 2-3.5 ml of Perfluorane dissolved in 2 ml of physiologic saline into vagina of patient's female partner before sexual contact. The woman remains in rest in horizontal position lying on her back during 15-20 min after having accomplished sexual contact. The treatment is started 2 days before ovulation and takes place before every sexual contact during 5-7 days, continuing it in following ovulation cycles until fertilization takes place.
Method for treating female tubo-peritoneal sterility cases after plastic reconstruction operations / 2316332
Method involves applying therapy course containing iodine-bromine baths and vaginal irrigations given every other day. Electrophoresis is administered in days free of baths and irrigations after 2 adaptation days with silt mud enriched in hydrogen sulfide water containing hydrogen sulfide in concentration of 350 mg/l. The treatment is applied to hypogastric and lumbosacral region at the level of L4-S2 vertebrae. Electric current intensity is equal to 0.05-0.1 MA/cm2 during 20 min. The total treatment course is 8 balneo- and physioprocedures long.
Method for correcting reproductive health in females / 2314094
It is necessary to fulfill combined impact upon hypothalamo-hypophysial-ovarian system due to simultaneous introduction of vascular and nootropic metabolics (for example, kavinton and glycine), multivitamins including the group out of seven vitamins "B" (folic and pantothenic acids among them), and hepatoprotectors (chophytol). They should be introduced for the period of 2 mo. The innovation provides complex impact upon all the links in the system of hypothalamo-hypophysial-ovarian system, normalization of metabolism and, thus, normalization of menstrual cycle.
Method for increasing qualitative parameters of sperm / 2311912
The present innovation deals with treating sterility, at intrauterine insemination and extracorporal fertilization. For implementing the method suggested it is necessary to dilute 0.4 ml ejaculate in 0.4 ml physiological solution (0.9%-NaCl solution), then one should add about 0.3-0.6 ml perfluoran to keep at mixing and shaking for 3 min. The innovation enables to increase qualitative parameters of sperm: increase the number of mobile spermatozoa in ejaculate, increase respiratory ability of spermatozoa, increase Farris' calculation value that increases the probability for fertilization.
 Method for treatment of endometriosis or infertility, or improving of fertility and pharmaceutical composition therefor / 2310474
Invention relates to topical pharmaceutical composition for treatment of endometriosis or infertility, or improving of fertility. Claimed composition contains therapeutically effective amount of β-adrenergic agonist and pharmaceutically acceptable carrier. Aldo disclosed are method for treatment of abovementioned disorders and drug for vagina mucous administering, containing therapeutically effective amount of β-adrenergic agonist and pharmaceutically acceptable carrier.
 Preparation for normalizing female reproductive function and method for its obtaining / 2303454
The present innovation deals with isolating biologically active substance out of animals' ovaries to obtain medicinal form for parenteral intake that could be applied as a remedy to normalize female reproductive function. This preparation is being a peptide complex at the content of low-molecular fraction ranged 70-90%, at molecular weight of peptide components in it being within 70-712 Da, at concentration of polypeptides ranged 2.5÷2.9 mg/ml and obtained out of the ovaries of 12-mo-aged calves, not older or from swine due to extracting acetic acid in the presence of zinc chloride. The suggested technique for obtaining the preparation mentioned deals with the fact that ovaries from calves or swine's should be frozen at -40°C, not less to be kept at -20÷22°C for 2 mo, not less to be then reduced, 3%-acetic acid solution should be added at volumetric ratio of 1:5 at 20°±5°C; extraction should be fulfilled at constant mixing and on obtaining homogeneous suspension it should be supplemented with 1%-zinc chloride solution at volumetric ration of 7°÷16°C, then it is necessary to mix per 1 h in every 4 h keeping for 48 h, the extract should be separated against ballast substances due to separating, the extract should be supplemented with acetone at volumetric ratio of 1:5 to be kept at 3÷5°C for 4 h, the developed homogenized residue should be repeatedly precipitated with acetone twice, not less, then the residue that contains an active substance should be washed upon Nutsch filter with 2-fold volumes of acetone (cooled up to 7÷16°C) till obtaining the residue of light-gray color, grated through metallic sieve, dried, dissolved in distilled water at a room temperature and constant mixing up to polypeptides concentration being 2.5÷2.9 mg/ml,; the solution should be centrifuged, filtered and purified ultrafiltrationally upon the equipment at anti-pressure being not more than 1.0 kilogauss/sq. cm through materials at inhibiting capacity of 15000 Da, ultrafiltrate should be supplemented with glycocoll up to its final concentration being 10÷20 mg/ml at pH=5.6÷6.6, the solution should undergo sterilizing filtration at the pressure being not more than 2.0 kilogauss/sq. cm to be poured into ampoules per 2 ml and autoclaved for 8 min at 120°C and atmospheric pressure of 1.1 kilogauss/sq. cm. The innovation provides optimal technology to isolate peptide complex at the content of low-molecular fraction from 70 to 90% at molecular weight of peptide components in it ranged 70-712 Da and obtain water solution of the extract at concentration of polypeptides being 2.5÷2.9 mg/ml that enables not only purify the obtained product against admixtures but increase its output; and, also, the isolated substance is distinct against known ones obtained earlier out of animal ovaries by molecular weight of peptide complexes in it and by its nontoxicity and apyrogeneity due to complete purification against admixtures.
 Agent normalizing reproductive function in men and method for its preparing / 2302874
Invention relates to a method for isolating active substance from mammalian testicles and preparing a medicinal formulation for parenteral administration that can be used in medicine as agent normalizing the reproductive function in men. Agent is made as a medicinal formulation for parenteral administration and represents peptide complex with the content of low-molecular fraction from 70% to 90%, molecular mass of its peptide components in the range 75-228 Da, and concentration of polypeptides 2.5-2.9 mg/ml. Agent is prepared from mature young bull testicles (age is 12 months, not above) or pigs by tissue extraction with acetic acid in the presence of zinc chloride. Proposed method for preparing agent involves freezing mature young bull testicles (age is 12 months, not above) or pigs at temperature -40°C (not less), keeping at temperature -20-22°C for two months (not less), milling and adding 3% acetic acid solution in the volume ratio = 1:5 at temperature 20 ± 5°C. Extraction is carried out at constant stirring and 1% zinc chloride solution is added to the prepared homogenous suspension in the volume ratio = 50:1 followed by cooling at constant stirring up to temperature 7-16°C and the following stirring for 1 h in each 4 h in settling for 48 h. Extract is separated from inert substances by separating and acetone is added to extract in the volume ratio = 1:5, kept at temperature 3-5°C for 4 h. Formed homogenized deposit is precipitated with acetone repeatedly twice (not less) and deposit containing active substance is washed out on Nutch filter with two-fold volumes of acetone cooled to temperature 7-16°C up to preparing light-gray deposit. Deposit is rubbed through metallic sieve, dried, dissolved in distilled water at room temperature at constant stirring up to the concentration of polypeptides 2.5-2.9 mg/ml. Solution is centrifuged, filtered and subjected for ultrafiltration treatment in device under anti-pressure 1.0 kgf/cm2 (not above) through materials with retaining capacity 15000 Da. Glycocol is added to ultrafiltrate to its final concentration 10-120 mg/ml at pH = 5.6-6.6 and solution is subjected for sterilizing filtration under pressure 2.0 kgf/cm2 (not above), poured into ampoules in volume 2 ml and subjected for autoclaving at temperature 120°C for 8 min and under atmosphere pressure 1.1 kgf/cm2. Invention provides optimal technology in isolating peptide complex with the content of low-molecular fraction from 70% to 90%, molecular mass of its peptide components in the range 75-228 a, and preparing aqueous solution of extract with the concentration of polypeptides 2.5-2.9 mg/ml. Invention provides both purifying the prepared product from impurities and to enhance its yield. The isolated substance differs from the known substances early prepared from mammalian raw by molecular mass of its peptide components, absence of toxicity and apyretic properties based on the complete removing impurities.
Method for treating anovulatory sterility cases / 2299742
Method involves introduced Tanacan 40 mg three times a day 3 months long course. Magne B6 is concurrently introduced at a dose of 2 pills twice a day during 40 days. Endonasal Dalargin electrophoresis is additionally applied daily for 15-20 min. The total treatment course is 12 procedures long.
![Derivatives of thieno[2,3-d]pyrimidine and their using in treatment of fertility disorder](http://img.russianpatents.com/img_data/128/1284848-s.gif) Derivatives of thieno[2,3-d]pyrimidine and their using in treatment of fertility disorder / 2298011
Invention relates to derivatives of thieno[2,3-d]pyrimidine of the general formula (I):
 Methods and materials for treating testosterone failure in men / 2297218
The present innovation deals with the method of applying compositions containing trans-clomiphen and cis-clomiphen in the ratio by weight being above or equal 71/29 for increasing the level of testosterone in blood serum in male mammalian. Application of practically pure trans-clomiphen according to the present innovation provides increased level of testosterone both at the decrease and at sufficient content of this hormone, in case of necessity or desirability of such an increase for a mammalian, at decreased number of side effects as a result of clomiphen-based therapy.
Method for treating cases of secretory masculine infertility form / 2317071
Method involves introducing 2-3.5 ml of Perfluorane dissolved in 2 ml of physiologic saline into vagina of patient's female partner before sexual contact. The woman remains in rest in horizontal position lying on her back during 15-20 min after having accomplished sexual contact. The treatment is started 2 days before ovulation and takes place before every sexual contact during 5-7 days, continuing it in following ovulation cycles until fertilization takes place.
Method for treating wounds / 2314756
It is necessary to fulfill the tamponade with a bandage with oxygenated perfluoran in a frozen form. The bandage should be applied till carrying out primary surgical treatment of a wound, for 4 d but not longer 2-4 times daily. The innovation enables to improve microcirculation in wound area, decrease the risk of suppuration, postpone if necessary the terms of primary surgical treatment of the wound.
Method for treating facial furuncles / 2311933
It is necessary to fulfill ultrasound treatment of the wound with perfluoran twice or thrice per about 3060 sec. The it is important to apply a perfluoran-containing bandage for about 3-4 d. For the purpose to avoid drying of this bandage it is necessary to install there a thin catheter through which, by fractions, one should introduce perfluoran 3-4 times daily. The innovation accelerates the process of wound purification, improves tissue reparation due to efficient tissue oxygenation and, thus, develop a slightly visible cosmetic cicatrix.
Method for treating endophthalmitis and uveitis of unknown and viral etiology / 2311173
It is necessary to introduce parabulbarly per about 0.3-0.5 ml perfluoran once daily for 10 d. Moreover, one should prescribe intravenous laser blood irradiation that enables to shorten terms of therapy, exclude side effects and maximally decrease the number of relapses.
 Method for applying sevofluran anesthetic preparation at aortocoronary bypass operations and prosthetics of cardiac valves in adult patients during artificial circulation / 2309771
The suggested innovation could be applied as anesthesiological means in the course of aortocoronary bypass operations and prosthetics of cardiac valves in adult patients during artificial circulation due to the following technique: out of narcosis apparatus one should supply sevofluran due to inhalations with oxygen-air mixture into oxygenator's contour. The supply of this anesthetic preparation should be fulfilled in the course of the whole period of artificial circulation. The innovation enables to optimize anesthesiological means during operations upon open heart due to uninterrupted supply of sevofluran in the course of the whole surgical interference, during occlusion of aorta and removal of heart and lungs out of circulation, as well.
General anesthesia method in carrying out cheilorhinoplastic operations in small children / 2308980
Method involves introducing anesthetics and setting laryngeal mask. Then, general anesthesia is administered in bolus dose by making Sevofluorane inhalations of concentration equal to 8% by volume when observing child anxiousness manifestations, the concentration supported at the level of 3-6% by volume after consciousness has been lost to pupil centering state. No anxiousness manifestations being shown, induction is carried out step-by-step beginning with Sevofluorane concentration of 1% by volume augmenting it by 0.5% every 3-4 inspirations. General anesthesia is supported at the level of 1.5-2% by volume. Before making incision, Phentanyl is introduced.
Method for treating ischemic form of diabetic foot syndrome along with distal type of lesion in arteries of inferior limbs / 2308945
One should intravenously inject perfluoran 12 h before operation at the dosage of 5 mg/kg body weight along with inhaling oxygen-enriched air mixture. In the course of operation perfluoran should be injected intraarterially at the dosage of 100 ml. Such a scheme for introducing perfluoran provides maximal manifestation of its gas-transport function that enables to carry out efficient therapy due to considerable decrease of tissue hypoxia.
Method for treating odontogenous face and neck phlegmon cases / 2307597
Method involves carrying out surgical intervention and then local Perfluorane introduction. Perfluorane is introduced into wound by means of fractional dialysis and magnetophoresis.
 Emulsion of perfluoroorganic compounds with gas transmission properties surfactant of such emulsion and method for production thereof / 2305543
Invention relates to application of tocopherol polyethylene glycol ester application as surfactant to produce emulsion of perfluoroorganic compounds with gas transmission properties. Said emulsion contains 20 % of mixture of perfluoroorcanic compounds comprising perfluorodecaline and perfluoro-n-methylcyclohexyl piperidine in ratio of 2:1 and surfactant such as tocopherol polyethylene glycol ester or mixture thereof with proxanol. Method for production of abovementioned emulsion includes stabilizing of perfluorodecaline and perfluoro-n-methylcyclohexyl piperidine mixture with surfactant such as tocopherol polyethylene glycol ester or mixture thereof with proxanol, and emulsion is produced under homogenization pressure from 20 to 60 MPa with amount of homogenization cycles up to 30.
Method for carrying out general anesthesia in vitreoretinal surgery / 2304963
Method involves carrying out premedication with following induction into narcosis by introducing hypnotic drug Propophol at a dose of 1.2-1.5 mg/kg and micro-relaxant Tracrium at a dose of 0.5-0.6 mg/kg. Trachea intubation is carried out or laryngeal mask is set, and surgeon applies subtenon anesthesia in inferior internal quadrant by introducing 2 ml of 0.5 % Naporin and starts surgical intervention. Anesthesia is supported with nitrous oxide and oxygen mixture taken in 2:1 proportion and analgesic Sevoran at a dose of 0.5-1.2% by volume. Tracrium is additionally introduced at a dose of 0.03 mg/kg/h in micro-jets using syringe dosing unit. Anesthesiologist increases Sevoran dose to 3.5-4.5 % by volume on surgeon signal at operation stages having more expressed pain response, 30 s before beginning the work in the zone and on surgeon signal when increased pain sensitivity zone is passed over, Sevoran dose is restored to initial level. Antiemetic Zofran is introduced at a dose of 4 mg at the beginning or at the end of operation.
Method for treating odontogenic phlegmons of oral area / 2244518
In case of patient's average-severe or severe state before surgical interference or at satisfactory state - after surgical interference one should intravenously once introduce perfluorane at the dosage of 1-3 ml/kg body weight followed by daily treatment of the wound with perfluorane, washing and introducing perfluorane-impregnated gauze tampons till the end of exudation phase. The method enables to widen the number of preparations to treat odontogenic phlegmons of oral area, simplify therapeutic technique due to excluding the work with patient's blood, accelerate the process of purification and regeneration of soft tissues in the region of inflammation and shorten therapy terms.
|
FIELD: medical engineering. SUBSTANCE: method involves selecting sperm. Physiologic saline is added to the sperm and centrifuged twice 10 min long at 1500 rpm. Perfluorane is introduced into the produced spermatozoon mass in 1:3 proportion. It is held 3-5min long and the produced mixture is introduced into uterine cavity. EFFECT: increased mobility and respiratory capabilities of spermatozoa in azoaspermia cases; higher pregnancy onset probability. 1 tbl
The invention relates to medicine, in particular to urology, andrology, gynecology, and can be used to increase the likelihood of pregnancy with intrauterine insemination. The problem of infertility is an important part of modern medicine. It is not only medical but also a social problem. It is known that if the frequency of infertile marriages reaches or exceeds the critical level of 15%, the problem of infertility in this case acquires the state value. According to epidemiological studies, the frequency of infertile couples currently ranges up to 25%, and in some regions of the Russian Federation has a tendency to increase. Therefore, the treatment of infertility should be considered as a reserve of birth wanted children and the future increase the reproductive potential of the population of the Russian Federation. Thus, infertility is not only for specific individuals, but also affects society as a whole, reducing social and professional activity of this group of the population. The last decades of the twentieth century, significant advances in the diagnosis of various forms of infertility. The least addressed aspect of the problem of infertility is the treatment of various forms of male infertility. Methods of assisted re roductive technologies and their modification is not always possible to solve the problem of paternity with oligozoospermia, asthenozoospermia etc. For example, the probability of pregnancy after insemination is 10-15%. To date, no clear, evidence-based algorithm, revealing the etiology, the pathogenesis of various disorders of spermatogenesis and provide effective guidelines for the diagnosis and treatment of various forms of male infertility. Therefore, future prospects in the restoration and preservation of reproductive function person must be in fundamental research, to evaluate the mechanisms of the processes of ovulation, spermatogenesis, fertilization, implantation of the egg and the embryo (knowledge of the above mechanisms will determine the effective conduct a series of preventive and therapeutic measures aimed at the restoration and preservation of reproductive function), the development of new medical technologies of assisted reproduction techniques, new products and schemes stimulate ovulation and spermatogenesis, improvement of methods of organization of the treatment process. The known method of increasing the fertilizing ability of sperm to [the Application for invention No. 2000119029, IPC 61D 19/02; Dererences VI, Bortnikov A.M., Shlygin A.N., Sheiko H., consisting of the introduction into the environment of biologically active substances (BAS) is a synthetic analogue of prostaglandin F2α-soda is a salt eve of cloprostenol at a concentration of 200 μg per 100 ml of diluted semen. The disadvantage of this method is that a synthetic analogue of prostaglandin F2α-cloprostenol sodium salt has the ability to penetrate intact skin, and therefore caution should be exercised in working with the drug, especially women of childbearing age and asthmatics. Prostaglandin F2 alpha can cause bronchospasm people. The method is limited in application and does not allow its use at asthenozoospermia. Known method for improving the quality of sperm by prospermia in the program of in vitro fertilization [Patent RU No. 2205047, M CL 61N 5/067; Gavrilov Y.A., Kuzmichev, L.N., Leonov BV, Levchuk T.N., BIPM No. 2205047, IPC A61N 5/067, TPMF No. 15, 27.05.03, s.353], namely, that a patient with infertility should be performed within two weeks: 7-10 procedures laser stimulation in the pulse mode of the prostate, laser stimulation is carried out by establishing sensors simultaneously on the perineum and suprapubic region with a frequency of 0.6 kHz, a power of 3.5 W, lasting 8-10 minutes, and testicles with a frequency of 0.3 kHz, a power of 1.5 W, duration 7-9 minutes, 5-7 treatments stimulating massage of the prostate. Assign: amino acid chelate zinc and 22 mg selenium 200 mcg 2 times a day, puregon 50 ME intramuscularly daily for months. The disadvantage of this method is that the laser has a PR is tyopoytani in acute inflammatory processes, malignant tumors and tuberculosis. In addition, the appointment of puregon is contraindicated in severe liver and/or kidneys. Contraindications chelate of zinc are: acute glomerulonephritis, acute exacerbation of peptic ulcer aetiology. The method is limited in application and does not allow its use at asthenozoospermia. There is a method of sperm preparation for intrauterine insemination, including fence sperm preparation for insemination on how to "swim up", consisting in the laundering of spermatozoa from seminal plasma seminal plasma contains substances that suppress the activity of spermatozoa in saline solution by double centrifugation for 10 minutes at 1500 rpm. Do artificial insemination with husband's sperm, which is injected into the woman's vagina without intercourse. In the entire volume of the sperm gets into the throat area of the cervix, and not a small part, as it happens during intercourse. Accordingly, several times increases the likelihood of conception. On the day of ovulation processed and concentrated husband's sperm in a nutrient medium through the cervix is introduced into the uterine cavity. If after the 6th attempt pregnancy has not occurred, then move on to the next fertilization method. Procedure intrauterine insemi the purpose painless, since the sperm is injected using a special catheter with a very small diameter, which passes through the cervical canal. The duration of intrauterine insemination takes about 2 minutes. After the procedure the woman is in a horizontal position for 20-30 minutes [Barren marriage. Methods of assisted reproductive technology. Guide for clinicians, edited by V.I. Kulakov M, GEOTAR media 2005, str-444]. The disadvantage of this method is that the efficiency of the method is only 10-15%, and a satisfactory quality of sperm - the number of motile sperm should be more than 10 million for the insemination. The method cannot be applied when asthenozoospermia - pathological decrease in the number of motile sperm. The OBJECTIVE of the INVENTION: development opportunities intrauterine insemination with asthenozoospermia - reducing the number of motile sperm by improving the quality of semen by increasing sperm motility and their breathing abilities that can increase the probability of pregnancy after intrauterine insemination. This object is achieved in that conduct sperm preparation for intrauterine insemination by sperm is collected, add physiologist the ical solution and double centrifugation of the mixture for 10 minutes at 1500 rpm. After centrifugation the mass of spermatozoa enter the perftoran in the ratio of 1:3, incubated for 3-5 minutes, then injected into the cavity of the uterus. The novelty of the METHOD: After centrifugation the resulting mass of sperm mixed with perftoran to improve sperm quality: increasing the activity of live sperm and their breathing abilities. - Incubated for 3-5 min, which provides a more complete interaction of spermatozoa with perftoran, and introduce the mixture into the cavity of the uterus. We first perftoran was applied for the treatment of secretory forms of male infertility. When mixing of perftoran and sperm marked improvement of its quality indicators received a new technical result: increase in the number of motile sperm in the ejaculate, increase breathing capacity of spermatozoa, and thus fertilizing capacity, resistance, increase the estimated prevalence of Farris that allows you to increase the number of impregnations by 60-70 %. Thus, the proposed method can improve the probability of pregnancy after intrauterine insemination by improving sperm quality, increase motor activity of sperm that makes it applicable if asthenozoospermia - pathological nizeyimana motile sperm. Perftoran - perfluorocarbon compound emulsion-blood with the gas transport function, improves gas exchange and metabolism at the tissue level, which increases oxygen transport blood with membrane function, restoring Central hemodynamics, having a protective effect on the myocardium and slowly blocking incoming currents. Has sorption, diuretic properties, it improves the dynamics of blood flow and peripheral blood circulation. The oxygen capacity of perftoran 3 times higher oxygen capacity of the blood (Performancesee compounds in biology and medicine. Ivanitsky BORN, Pushchino; 1999; 1: s.; Local application of perftoran in the treatment of patients with widespread purulent peritonitis. Performancesee compounds in biology and medicine. Pushchino; 2001, p.137-141; Biophysical basis for the creation of perfluorocarbon environments and transmission of blood substitutes (review) / Performancesee compounds in biology and medicine. Pushchino; 2001, p.44-48). Indications: it is used as a blood substitute in the gas transport function during shock States, large blood loss, multiple trauma, burns, large surfaces of the body, liver cirrhosis, multiple skeletal injuries, carbon monoxide poisoning, combined lesions, peritoni is Oh, the state of clinical death, as well as in transplantation and organ transplants. The use of perftoran to improve sperm quality, increase the viability and activity of sperm to increase the efficiency of fertilization has not been previously used. THE METHOD IS AS FOLLOWS. Sperm preparation. Need sexual abstinence from 2 to 6 days (but not more than 6 days). Before sperm collection need to man urinated to clean the urethra. Penis and hands must be clean. By Masturbation sperm is collected in a special bottle and 20-30 minutes after liquefaction begins her training by the following method. - The laundering of spermatozoa from seminal plasma because seminal plasma contains substances that suppress the activity of spermatozoa. Why in the sperm add saline and spend double centrifugation for 10 minutes at 1500 rpm. Not active spermatozoa, seminal plasma, cell waste in this settle, and active sperm cells to rise to the top. - The collection of spermatozoa from the tube conduct laboratory pipette and mixed with perftoran in the ratio of 3 parts of perftoran and 1 part of the mass of sperm. - Stand-treated sperm in 3-5 minutes. Carry out the procedure on a regular gynecological chair by the conventional technology. On the day of ovulation is stimulated or natural cycle) treated and concentrated husband's sperm through the cervix and enter the uterus. Procedure intrauterine insemination painless, since the sperm is injected using a special catheter with a very small diameter, which passes through the cervical canal. The duration of intrauterine insemination takes about 2 minutes. After the procedure the woman is in a horizontal position for 20-30 minutes. If after the 6th attempt pregnancy has not occurred, then pass to other methods of fertilization. When using the husband's sperm this method is effective only when the sperm meets the defined quality parameters. If the sperm contains the number of motile sperm is reduced, what happens if asthenozoospermia, it is not possible to count on the possibility of fertilization through natural means or by intrauterine insemination and want to improve sperm quality, to increase the chance of fertilization. The woman must be healthy. We conducted a survey of 11 of infertile couples who have been married for 3 to 12 years. The cause of infertility in all cases - ACTE is azoospermia. Previously held the procedure intrauterine insemination was unsuccessful. The treatment by the proposed method. Fertilization and development of pregnancy occurred in 7 pairs. Within 1-4 attempts from the beginning of treatment.
As can be seen from the results table is optimal introduction of perftoran in the ratio of 1:3, as the dilution increases the maximum number of actively motile sperm. At higher dilution the number of actively motile sperm remains unchanged. Example 1. A couple Century, 25 and 33 years. Living married 8 years. Marriage is barren. When the EAC is adowanie at the gynecologist - wife healthy. Husband seeing a doctor-urologist for infertility in marriage for 5 years. A history of chronic prostatitis, epididymitis. On this occasion receives treatment at the present time. In the study of semen: sperm count is 69 million (OK - more than 40 million). Living - 52% (89-90%). Normokinetic (active translational motion) - 42% (over 80%). Respiratory ability of sperm - 11 minutes (normal 23-75 minutes). Rate Farris - 28,9. Conclusion: a significant decrease in motor activity of sperm. It was decided to conduct intrauterine insemination proposed method. Preparation of sperm for intrauterine insemination was performed by a fence of sperm separation of spermatozoa from semen dilution with saline and centrifugation. The washed sperm was mixed with perftoran in the ratio of 1:3, was kept for 5 minutes, the mixture was injected into the uterine cavity. Also conducted a study prepared and treated with perftoran sperm: sperm count is 69 million Live - 52%. Normokinetic - 77%. Respiratory ability of sperm - 42 minutes (normal 23-75 minutes). Rate Farris - 53,1. 18 days after insemination procedures spouse of the patient carried out a pregnancy test. Obtained a positive result is so Example 2. A couple R., 32, and 33 years. Living married 9 years. Marriage is barren. When examined by gynecologist - wife healthy. Husband seeing a doctor - urologist about chronic prostatitis. In the study of semen: sperm count is 86 million (OK - more than 40 million). Living - 68% (89-90%). Normokinetic (active translational motion) - 44% (over 80%). Respiratory ability of sperm - 17 minutes (normal 23-75 minutes). Rate Farris - 37,8. Conclusion: a significant decrease in motor activity of sperm. It was decided to conduct intrauterine insemination. Preparation of sperm for intrauterine insemination was performed by a fence of sperm separation of spermatozoa from semen dilution with saline and centrifugation. The washed sperm was mixed with perftoran in the ratio of 1:3, was kept for 3 minutes, the resulting mixture was injected into the uterine cavity. Also conducted a study prepared and treated with perftoran sperm: sperm count is 86 million Live - 68%. Normokinetic - 79%. Respiratory ability of sperm to 29 minutes. Rate Farris - 67,9. 18 days after insemination procedures spouse of the patient carried out a pregnancy test. A positive result. Example 3. A couple And., 29 and 36 years. W the CWF married 12 years. Marriage is barren. When examined by gynecologist - wife healthy. Husband seeing a doctor - urologist. History has endured mixed (mixed infection) Ureaplasma-chlamydial-Trichomonas urethritis 7 years ago, which was complicated by orchiepididymitis. On this occasion took the treatment, which is not finished. In the study of semen: sperm count is 160 million (OK - more than 40 million). Living - 56% (80-90%). Normokinetic (active translational motion) - 32% (over 80%). Respiratory ability of sperm - 10 minutes (normal 23-75 minutes). Rate Farris Of 51.2. The study was prepared and treated with perftoran sperm: sperm count is 160 million Live - 56%. Normokinetic - 79%. Respiratory ability of sperm to 29 minutes. Rate Farris - 126,4. Conclusion: a significant decrease in motor activity of sperm. It was decided to conduct intrauterine insemination. Preparation of sperm for intrauterine insemination was performed by a fence of sperm separation of spermatozoa from semen dilution with saline and centrifugation. The washed sperm was mixed with perftoran in the ratio of 1:3, was kept for 5 minutes, the mixture was injected into the uterine cavity. Only after the third attempt insemination conducted the test on beremennosti gave a positive result. With the addition of perftoran increases the quality of sperm, and it increases sperm motility and their breathing ability, which increases the likelihood of pregnancy after intrauterine insemination. The method allows the use of intrauterine insemination with asthenozoospermia. The method of preparation of sperm for intrauterine insemination, including the sperm is collected, add saline and double centrifugation for 10 min at 1500 rpm, characterized in that obtained after centrifugation mass of spermatozoa enter the perftoran in the ratio of 1:3 and incubated for 3-5 min and injected the mixture into the cavity of the uterus.
|
||||||||||||||||||||||||